Physiomics PLC Director Dealing

Fecha : 05/08/2019 @ 01:00
Fuente : UK Regulatory (RNS & others)
Emisora : Physiomics Plc (PYC)
Cotización : 2.55  0.0 (0.00%) @ 01:42
Physiomics Cotización de acciones Gráfica

Physiomics PLC Director Dealing

Physiomics (LSE:PYC)
Gráfica de Acción Histórica

6 Meses : De Jun 2019 a Dic 2019

Haga Click aquí para más Gráficas Physiomics.

TIDMPYC

RNS Number : 8063H

Physiomics PLC

05 August 2019

2 August 2019

Physiomics plc

("Physiomics") or (the "Company")

Director Dealing

The Company announces that it received notice today that Christophe Chassagnole, the Company's Chief Operating Officer, acquired 100,000 ordinary shares of 0.4 pence each in the capital of the Company ("Ordinary Shares") at 3.38 pence per share.

Following the acquisition, Dr Chassagnole is interested in 517,008 Ordinary Shares representing approximately 0.72% of the Company's issued share capital.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 20 3764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1    Details of the person discharging managerial responsibilities/person closely associated 
 a)   Name                                                                  Christophe Chassagnole 
     --------------------------------------------------------------------  ------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------------------------------- 
 a)   Position/status                                                       Director, COO 
     --------------------------------------------------------------------  ------------------------- 
 b)   Initial notification/ Amendment                                       Initial notification 
     --------------------------------------------------------------------  ------------------------- 
 3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
     ----------------------------------------------------------------------------------------------- 
 a)   Name                                                                  Physiomics plc 
     --------------------------------------------------------------------  ------------------------- 
 b)   LEI                                                                   213800A71DSZ6ABMTQ91 
     --------------------------------------------------------------------  ------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------------------------------------------- 
 a)   Description of the financial instrument, type of instrument           Ordinary share 
 
       Identification code 
                                                                             GB00BDR6W943 
     --------------------------------------------------------------------  ------------------------- 
 b)   Nature of the transaction                                             Acquisition of shares 
     --------------------------------------------------------------------  ------------------------- 
 c)   Price(s) and volume(s)                                                 Price(s)   Volume(s) 
                                                                              3.38p      100,000 
                                                                                        ---------- 
     --------------------------------------------------------------------  ------------------------- 
 d)    Aggregated information 
         *    Aggregated volume                                               100,000 
                                                                              At 3.38p 
 
         *    Price 
     --------------------------------------------------------------------  ------------------------- 
 e)   Date of the transaction                                               02-08-2019 
     --------------------------------------------------------------------  ------------------------- 
 f)   Place of the transaction                                              XLON, AIM 
     --------------------------------------------------------------------  ------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHPTMATMBJMBRL

(END) Dow Jones Newswires

August 05, 2019 02:00 ET (06:00 GMT)

Su Consulta Reciente
BMV
FIBRAPL14
Fibra Prol..
BMV
AMXL
América Mó..
BMV
ME
IPC México
BMV
ALSEA*
Alsea
FX
USDMXN
United Sta..
Las acciones que ha visto aparecerán en este recuadro, lo que le permite volver fácilmente a las cotizaciones que ha consultado previamente
Registrarse ahora para crear su lista personalizada de acciones en streaming.

Cotizaciones PLUS están en tiempo real. Cotizaciones NYSE y AMEX están con retraso de por lo menos 20 minutos.
El resto de las cotizaciones están con retraso de por lo menos 15 minutos al menos que se indique lo contrario.

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

P: V:mx D:20191216 10:50:22